CAM
TMO icon

Cresset Asset Management’s Thermo Fisher Scientific TMO Stock Holding History

Cresset Asset Management’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.3M Buy
48,390
+4,642
+11% +$2.23M 0.09% 147
2026
Q1 		$21.5M Buy
43,748
+1,516
+4% +$823K 0.09% 147
2025
Q4 		$24.5M Buy
42,232
+3,560
+9% +$2.01M 0.1% 125
2025
Q3 		$18.8M Buy
38,672
+5,793
+18% +$2.7M 0.08% 145
2025
Q2 		$13.3M Buy
32,879
+3,652
+12% +$1.53M 0.07% 177
2025
Q1 		$14.6M Sell
29,227
-740
-2% -$401K 0.07% 167
2024
Q4 		$15.6M Sell
29,967
-28,660
-49% -$15.8M 0.07% 165
2024
Q3 		$36.3M Buy
58,627
+4,918
+9% +$2.91M 0.14% 102
2024
Q2 		$29.7M Buy
53,709
+15,011
+39% +$8.6M 0.12% 109
2024
Q1 		$22.5M Buy
38,698
+7,637
+25% +$4.29M 0.11% 125
2023
Q4 		$16.5M Sell
31,061
-1,658
-5% -$803K 0.1% 141
2023
Q3 		$16.6M Buy
32,719
+1,071
+3% +$571K 0.06% 143
2023
Q2 		$16.5M Buy
31,648
+23,515
+289% +$12.7M 0.02% 195
2023
Q1 		$4.69M Sell
8,133
-1,031
-11% -$581K 0.09% 139
2022
Q4 		$3.36M Buy
9,164
+1,034
+13% +$548K 0.04% 155
2022
Q3 		$4.13M Sell
8,130
-1,326
-14% -$742K 0.05% 138
2022
Q2 		$4.68M Sell
9,456
-181
-2% -$99.6K 0.06% 133
2022
Q1 		$5.7M Sell
9,637
-2,441
-20% -$1.4M 0.06% 117
2021
Q4 		$8.06M Sell
12,078
-125
-1% -$78K 0.08% 107
2021
Q3 		$6.97M Buy
12,203
+1,733
+17% +$951K 0.09% 90
2021
Q2 		$5.28M Buy
10,470
+1,242
+13% +$586K 0.07% 99
2021
Q1 		$4.21M Buy
9,228
+1,140
+14% +$544K 0.07% 100
2020
Q4 		$3.77M Buy
8,088
+544
+7% +$255K 0.06% 106
2020
Q3 		$3.33M Buy
7,544
+149
+2% +$61.6K 0.06% 117
2020
Q2 		$2.68M Buy
7,395
+307
+4% +$103K 0.06% 120
2020
Q1 		$2.01M Buy
7,088
+210
+3% +$66.2K 0.06% 117
2019
Q4 		$2.24M Buy
6,878
+2,370
+53% +$719K 0.06% 130
2019
Q3 		$1.31M Buy
4,508
+529
+13% +$151K 0.04% 165
2019
Q2 		$1.17M Buy
3,979
+144
+4% +$39.7K 0.04% 161
2019
Q1 		$1.05M Buy
3,835
+987
+35% +$246K 0.04% 106
2018
Q4 		$638K Buy
+2,848
New +$668K 0.04% 105

Other funds holding TMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Cresset Asset Management's TMO Position: Q2 2026 in Review

Cresset Asset Management increased its Thermo Fisher Scientific (TMO) stake by 11% in Q2 2026, buying an estimated $2.23M and bringing the position to 48,390 shares worth $24.3M. The position accounts for 0.09% of the portfolio, ranked #147.

Cresset Asset Management first reported a position in TMO in Q4 2018 and has held it in 31 quarters since. The position peaked at $36.3M in Q3 2024. 2,604 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • Cresset Asset Management held 48,390 shares of Thermo Fisher Scientific worth $24.3M as of Q2 2026.
  • Cresset Asset Management bought 4,642 Thermo Fisher Scientific shares in Q2 2026, an estimated $2.23M.
  • Thermo Fisher Scientific made up 0.09% of Cresset Asset Management's portfolio in Q2 2026, its #147 holding.
  • Cresset Asset Management first reported a position in Thermo Fisher Scientific in Q4 2018 and has held it in 31 quarters since.
  • Cresset Asset Management's Thermo Fisher Scientific position peaked at $36.3M in Q3 2024.
  • 2,604 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.